Head to head comparison of two PET/CT imaging agents, [¹⁸F]D3FSP ([¹⁸F]P16-129) and [¹⁸F]AV45, in patients with alzheimer's disease.

ABSTRACT:

Background

A new β-amyloid (Aβ) targeting radiotracer, [¹⁸F]D3FSP ([¹⁸F]P16-129), for diagnosis of Alzheimer's disease (AD) is reported. This radiotracer is a deuterated N-methyl derivative of Amyvid (AV-45, florbetapir f18) which was FDA-approved in 2013. Deuteration may alter a tracer's PK such that imaging performance is improved. A head-to-head comparison between these two imaging agents was conducted in AD patients. A separate biodistribution study was conducted on six healthy subjects, and radiation dosimetry estimation was obtained.

Results

Eight patients, clinically diagnosed with Alzheimer's disease, had an average age of 61.1 ± 10.0 years, and an average MMSE score of 21 ± 4. Each patient underwent paired 90-minute dynamic PET/CT scans separat

SUBMITTER: Alexoff D 

PROVIDER: S-EPMC12183142 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature